Head to Head Survey: Protagonist Therapeutics (NASDAQ:PTGX) and Sera Prognostics (NASDAQ:SERA)

Protagonist Therapeutics (NASDAQ:PTGX) and Sera Prognostics (NASDAQ:SERA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Profitability

This table compares Protagonist Therapeutics and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Volatility and Risk

Protagonist Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Protagonist Therapeutics and Sera Prognostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02 million	203.90	-$130.15 million	$1.03	140.78
Sera Prognostics	$80,000.00	988.72	-$31.93 million	($0.67)	-2.99

Sera Prognostics has lower revenue, but higher earnings than Protagonist Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Protagonist Therapeutics and Sera Prognostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	2	16	0	2.89
Sera Prognostics	1	0	1	1	2.67

Protagonist Therapeutics presently has a consensus price target of $147.13, indicating a potential upside of 1.47%. Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 174.31%. Given Sera Prognostics’ higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Protagonist Therapeutics.

Insider and Institutional Ownership

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Protagonist Therapeutics beats Sera Prognostics on 10 of the 15 factors compared between the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.